Clobex

Clobex

Generic Name

Clobex

Mechanism

Clobex (clobetasol propionate) is a super‑potent topical corticosteroid.
• Acts as a high‑affinity glucocorticoid receptor agonist.
• Inhibits phospholipase A₂, reducing arachidonic‑acid release and subsequent prostaglandin / leukotriene synthesis.
• Suppresses transcription of inflammatory cytokines (IL‑1, TNF‑α, IL‑6), chemokines, and adhesion molecules.
• Enhances dermal collagen synthesis and reduces vascular permeability, yielding rapid anti‑inflammatory and anti‑pruritic effects.

Pharmacokinetics

Parameter Description
AbsorptionVery high local skin penetration; systemic absorption depends on dose, duration, and body surface area.
DistributionMainly confined to dermis‑epidermis; lipophilic, binds to plasma proteins when absorbed systemically.
MetabolismPrimary hepatic metabolism via CYP3A4/5 to inactive metabolites.
EliminationRenal excretion; half‑life ≈ 12 h (topical).
Systemic exposureLow when used appropriately; risk increases with large area, occlusion, or prolonged use.

Indications

  • Atopic dermatitis (moderate‑to‑severe).
  • Psoriasis vulgaris – short bursts (≤ 7 days).
  • Seborrheic dermatitis, cutaneous lupus erythematosus, sarcoidosis (localized).
  • Vulvovaginal and perianal dermatitis (short courses).
  • Keloid, hypertrophic scar – adjunctive therapy for reducing inflammation.

Contraindications

  • Active skin infection (bacterial, fungal, or viral).
  • Photosensitivity reactions – avoid concurrent photosensitizing agents.
  • Hirsutism or androgen‑sensitive skin disorders – caution.
  • Mucosal thinning or erosive lesions – contraindicated.
  • Use in pregnancy – category C; limited data, use only if benefits outweigh risks.

Warnings:
• Systemic corticosteroid effects (hypothalamic‑pituitary‑adrenal suppression, hyperglycemia, hypertension).
• Skin atrophy, striae, telangiectasia, pigmentary changes.
• Delayed wound healing, increased infection susceptibility.
Do not use on the face > 1–2 weeks in a row; limit facial use to ≤ 2 weeks total.
• Avoid use in children < 2 years; recommend caution in infants < 12 months.

Dosing

  • Application: Apply a thin layer to affected areas once or twice daily.
  • Duration:
  • *Eczema/psoriasis*: 1–2 weeks; discontinue and taper if extended.
  • *Vulvovaginal dermatitis*: 5–7 days.
  • Occlusion: Do not cover the area with occlusive dressings for > 48 h unless prescribed.
  • Children: Use with care; limit to ≤ 2 weeks and supervise for systemic signs.
  • Pregnancy: Short courses may be considered; monitor fetal development if prolonged use.

Adverse Effects

CategoryExamples
LocalSkin thinning, striae, telangiectasia, acneiform eruptions, hyperpigmentation, hypopigmentation.
SystemicHPA axis suppression, Cushingoid features, hyperglycemia, hypertension, adrenal crisis (rare).
OtherAllergic contact dermatitis, paradoxical rebound flare upon abrupt withdrawal.

Monitoring

  • Visual inspection of skin every 2–4 weeks for atrophy, striae, pigment changes.
  • Pulse, blood pressure, and fasting glucose in patients with diabetes or hypertension.
  • Pregnancy: Ultrasound if prolonged (> 4 weeks) use.
  • Baseline labs (CBC, CMP) if systemic absorption suspected (large BSA, occlusion, prolonged therapy).
  • Adrenal function (cosyntropin stimulation test) if tapering after > 4 weeks of use.

Clinical Pearls

  • Short, high‑intensity bursts are most effective for psoriasis; prolonged application rarely improves outcomes and increases systemic exposure.
  • Use micro‑dose (thinner layer) when treating sensitive areas (face, genitals) to mitigate atrophy risk.
  • Rotating to a lower‑potency steroid after initial control helps prevent rebound and preserves dermal integrity.
  • Co‑treat with moisturizers to maintain skin barrier and reduce dryness.
  • Avoid comedogenic vehicles (e.g., petroleum jelly) that can trap the drug and amplify systemic absorption.
  • Patient education: Emphasize “do not over‑apply” and “do not use on broken skin” to prevent infections.

--
• *Clobex (clobetasol propionate) is a high‑potency topical corticosteroid that provides rapid anti‑inflammatory benefit for a range of dermatoses when used judiciously. Monitoring for skin atrophy and systemic effects ensures safe, effective treatment.*

Medical & AI Content Disclaimers
Medical Disclaimer: Medical definitions are provided for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

AI Content Disclaimer: Some definitions may be AI-generated and may contain inaccuracies. Always verify with authoritative medical references.

Scroll to Top